T. Morioka

Dosage form design for improvement of bioavailability of levodopa IV: Possible causes of low bioavailability of oral levodopa in dogs.

K. Sasahara, T. Nitanai, T. Habara, 1981, Journal of pharmaceutical sciences.

KINETICS OF THE METABOLISM OF ACETAMINOPHEN BY HUMANS.

E. Nelson, T. Morioka, 1963, Journal of pharmaceutical sciences.

High-performance liquid chromatographic method for determination of cefmetazole in human serum

K. Sasahara, M. Sekine, T. Kojima, 1982, Antimicrobial Agents and Chemotherapy.

Dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and parkinsonian patients.

K. Sasahara, T. Nitanai, T. Habara, 1980, Journal of pharmaceutical sciences.

Dosage form design for improvement of bioavailability of levodopa III: Influence of dose on pharmacokinetic behavior of levodopa in dogs and Parkinsonian patients.

K. Sasahara, T. Nitanai, T. Habara, 1980, Journal of pharmaceutical sciences.

Dosage form design for improvement of bioavailability of levodopa V: Absorption and metabolism of levodopa in intestinal segments of dogs.

K. Sasahara, T. Nitanai, T. Habara, 1981, Journal of pharmaceutical sciences.